6 O
ADVERSE O
REACTIONS O
Serious O
and O
important O
adverse O
reactions O
described O
elsewhere O
in O
labeling O
include O
: O
* O
Gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reactions O
in O
clinical O
trials O
( O
> O
= O
3 O
% O
) O
are O
: O
abdominal O
pain O
, O
diarrhea O
, O
nausea O
, O
flatulence O
, O
vomiting O
, O
and O
headache O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AstraZeneca O
at O
1-800-236-9933 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
MOVANTIK O
in O
1497 O
patients O
in O
clinical O
trials O
, O
including O
537 O
patients O
exposed O
for O
greater O
than O
six O
months O
, O
and O
320 O
patients O
exposed O
for O
12 O
months O
. O

The O
safety O
data O
described O
in O
Table O
1 O
are O
derived O
from O
two O
double-blind O
, O
placebo-controlled O
trials O
( O
Studies O
1 O
and O
2 O
) O
in O
patients O
with O
OIC B-Not_AE_Candidate
and O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
related I-Not_AE_Candidate
pain I-Not_AE_Candidate
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Study O
3 O
( O
n=302 O
) O
was O
a O
safety O
extension O
study O
that O
allowed O
patients O
from O
Study O
1 O
to O
continue O
the O
same O
blinded O
treatment O
for O
an O
additional O
12 O
weeks O
. O

Safety O
data O
for O
patients O
in O
Study O
3 O
are O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Study O
4 O
( O
n=844 O
) O
was O
a O
Phase O
3 O
, O
52-week O
, O
multi-center O
, O
open-label O
, O
randomized O
, O
parallel O
group O
, O
safety O
and O
tolerability O
study O
of O
naloxegol O
versus O
usual O
care O
treatment O
for O
OIC O
( O
as O
determined O
by O
the O
investigator O
and O
excluding O
peripheral O
opioid O
antagonists O
) O
in O
patients O
with O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cancer I-Not_AE_Candidate
related I-Not_AE_Candidate
pain I-Not_AE_Candidate
. O

The O
population O
enrolled O
in O
Study O
4 O
was O
similar O
to O
that O
of O
the O
other O
studies O
. O

Eligible O
patients O
were O
randomized O
in O
a O
2:1 O
ratio O
to O
receive O
either O
naloxegol O
25 O
mg O
once O
daily O
or O
usual O
care O
treatment O
for O
OIC B-Not_AE_Candidate
. O

The O
most O
commonly O
used O
laxatives O
in O
the O
usual O
care O
group O
were O
rectal O
stimulants O
( O
e.g. O
, O
bisacodyl O
) O
, O
oral O
stimulants O
( O
e.g. O
, O
senna O
) O
, O
and O
oral O
osmotics O
( O
e.g. O
, O
macrogol O
, O
magnesium O
) O
. O

Safety O
data O
for O
patients O
in O
Study O
4 O
are O
similar O
to O
those O
listed O
in O
Table O
1 O
. O

Table O
1 O
lists O
adverse O
reactions O
in O
pooled O
Studies O
1 O
and O
2 O
occurring O
in O
> O
= O
3 O
% O
of O
patients O
receiving O
MOVANTIK O
12.5 O
mg O
or O
25 O
mg O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

Table O
1 O
. O

Adverse O
ReactionsAdverse O
reactions O
occurring O
in O
> O
=3 O
% O
of O
patients O
receiving O
MOVANTIK O
12.5 O
mg O
or O
25 O
mg O
and O
at O
an O
incidence O
greater O
than O
placebo O
. O

in O
Patients O
with O
OIC B-Not_AE_Candidate
and O
Non B-Not_AE_Candidate
- I-Not_AE_Candidate
Cancer I-Not_AE_Candidate
Pain I-Not_AE_Candidate
( O
Studies O
1 O
and O
2 O
) O
Adverse O
Reaction O
MOVANTIK O
25 O
mg O
( O
n=446 O
) O
MOVANTIK O
12.5 O
mg O
( O
n=441 O
) O
Placebo O
( O
n=444 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
21 O
% O
12 O
% O
7 O
% O
Diarrhea B-OSE_Labeled_AE
9 O
% O
6 O
% O
5 O
% O
Nausea B-OSE_Labeled_AE
8 O
% O
7 O
% O
5 O
% O
Flatulence B-OSE_Labeled_AE
6 O
% O
3 O
% O
3 O
% O
Vomiting B-OSE_Labeled_AE
5 O
% O
3 O
% O
4 O
% O
Headache B-OSE_Labeled_AE
4 O
% O
4 O
% O
3 O
% O
Hyperhidrosis B-OSE_Labeled_AE
3 O
% O
< O
1 O
% O
< O
1 O
% O
Opioid B-OSE_Labeled_AE
Withdrawal I-OSE_Labeled_AE
Possible O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
, O
defined O
as O
at O
least O
three O
adverse O
reactions O
potentially O
related O
to O
opioid B-OSE_Labeled_AE
withdrawal I-OSE_Labeled_AE
that O
occurred O
on O
the O
same O
day O
and O
were O
not O
all O
related O
to O
the O
gastrointestinal O
system O
, O
occurred O
in O
less O
than O
1 O
% O
( O
1/444 O
) O
of O
placebo O
subjects O
, O
1 O
% O
( O
5/441 O
) O
receiving O
MOVANTIK O
12.5 O
mg O
, O
and O
3 O
% O
( O
14/446 O
) O
receiving O
MOVANTIK O
25 O
mg O
in O
Studies O
1 O
and O
2 O
regardless O
of O
maintenance O
opioid O
treatment O
. O

Symptoms O
included O
but O
were O
not O
limited O
to O
hyperhidrosis B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
, O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
and O
yawning B-NonOSE_AE
. O

Patients O
receiving O
methadone O
as O
therapy O
for O
their O
pain O
condition O
were O
observed O
in O
Studies O
1 O
and O
2 O
to O
have O
a O
higher O
frequency O
of O
gastrointestinal B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
than O
patients O
receiving O
other O
opioids O
[ O
39 O
% O
( O
7/18 O
) O
vs O
. O
26 O
% O
( O
110/423 O
) O
in O
the O
12.5 O
mg O
group O
; O
75 O
% O
( O
24/32 O
) O
vs O
. O
34 O
% O
( O
142/414 O
) O
in O
the O
25 O
mg O
group O
] O
. O

